Skip to main content

Table 2 The CYP2D6 genotype frequency

From: Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

  Genotype N = 279 Frequency (%)
EM/EM *1/*2 44 15.8
n = 87 (31.2 %) *1/*1 33 11.8
  *2/*2 10 3.6
EM/IM *1/*41 24 8.6
n = 43 (15.4 %) *2/*41 10 3.6
  *1/*10 7 2.5
  *2/*10 2 0.7
EM/PM *1/*4 51 18.3
n = 97 (34.8 %) *2/*4 30 10.8
  *1/*5 6 2.2
  *1/*3 4 1.4
  *2/*5 3 1.1
  *1/*6 1 0.4
  *2/*3 1 0.4
  *2/*6 1 0.4
IM/IM *41/*41 1 0.4
n = 3 (1.1 %) *10/*10 1 0.4
  *10/*41 1 0.4
IM/PM *4/*41 6 2.2
n = 11 (3.9 %) *4/*10 3 1.1
  *4/*17 1 0.4
  *5/*41 1 0.4
PM/PM *4/*4 15 5.4
n = 20 (7.2 %) *3/*4 2 0.7
  *4/*5 2 0.7
  *4/*6 1 0.4
UM *1/*2 (xN) 10 3.6
n = 18 (6.5 %) *1/*1 (xN) 5 1.8
  *2/*2 (xN) 3 1.1
  1. EM extensive-metabolizer, IM intermediate-metabolizer, PM poor-metabolizer, UM ultra-rapid-metabolizer